40 results about "M2 phenotype" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The invention belongs to the field of gene engineering, and particularly relates to a construction method of a gene engineering strain for producing glucosamine, a product and application. According to the method, intestinal probiotics with colonization ability are taken as an original strain, and multi-round CRISPR-Cas9 and Red homologous recombination technology combined transformation is carried out: on the basis of knockout of manX, ptsG is knocked out, a gna1 gene cluster derived from saccharomyces cerevisiae is inserted, then nagE is knocked out, and glmS driven by a strong promoter is inserted. In cell co-culture, the strain can safely and effectively promote phenotype transformation of a murine microglial cell line from BV2 to M2. In an animal model, the strain can colonize intestinal tracts in a short time and produce glucosamine, the effective concentration duration of glucosamine in serum is remarkably prolonged, inflammation is continuously inhibited, and the effect of enhancing immunity is achieved. And the strain does not have obvious toxicity, so that a new way is opened up for treating inflammatory diseases of engineering probiotics.

The invention discloses a compound capable of treating skin wounds and a preparation method and application of the compound, relates to the field of skin wound healing, and aims to solve the problems that in the prior art, photo-thermal treatment cannot be compatible with sterilization and weak tissue damage, and sanshool is unstable and easy to degrade, the adopted technical scheme is that PCM is used for loading sanshool and TIIG NPs. Light energy can be converted into heat energy under the mild photo-thermal condition, then phase change of the phase change material lipidosome is promoted, sanshool is released, physical sterilization and chemical sterilization effects are achieved at the same time, the obvious antibacterial effect on staphylococcus aureus and escherichia coli in vitro is achieved, macrophages can be promoted to be polarized to anti-inflammatory M2 phenotype, and the anti-inflammatory effect of the phase change material lipidosome is improved. The wound surface inflammation reaction is relieved. And the compound can completely inhibit the growth of bacteria, promote collagen deposition and realize complete healing of infected wounds within 12 days. The compound has efficient antibacterial and tissue repair functions and is good in biocompatibility.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The application provides an amphiphilic functionalized D-form-alanine and a preparation method and application thereof, and a self-targeting carbon monoxide nanogenerator and a preparation method and application thereof, and belongs to the technical field of antibacterial materials. The application provides an amphiphilic functionalized D-form-alanine. The self-targeting carbon monoxide nanogenerator prepared by using the amphiphilic functionalized D-form-alanine changes the permeability of the outer membrane of the cell wall of gram-negative bacteria, is metabolically utilized by bacteria in a specific manner, generates CO under the action of light to kill bacteria, removes biofilms that are not easy to touch and are hidden in deep periodontal pockets, simultaneously relieves inflammation by inducing macrophages to polarize from an M1 phenotype to an M2 phenotype, further promotes alveolar bone regeneration, and avoids damage to normal tissues.

The invention relates to the field of biological medicines, in particular to application of a reagent for inhibiting CYBB expression of tumor-associated macrophages in preparation of medicines for treating liver cancer and sensitizing a PD-1 inhibitor. The invention reveals that CYBB + TAMs can be used as a marker of poor curative effect of PD-1 on treating liver cancer for the first time. Targeted CYBB can activate a cGAS-STING pathway by reprogramming tumor-related macrophages from an M2 phenotype (tumor promotion) to an M1 phenotype (tumor resistance), and then improve the tumor killing function of CD8 + T cells, thereby inhibiting the growth of liver cancer and promoting the curative effect of a PD-1 inhibitor on liver cancer. By inhibiting the CYBB gene, the growth of the liver cancer can be inhibited, and the sensitivity of the liver cancer to a PD-1 inhibitor can be improved, so that the curative effect of immunotherapy is improved.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The invention discloses application of radix trichosanthis polysaccharide to preparation of a medicine for regulating immunity and inhibiting postoperative recurrence of colorectal cancer. The radix trichosanthis polysaccharide is found to be capable of promoting M2 phenotype macrophages to be polarized to M1 phenotype, and has an immunoregulation function; meanwhile, proliferation of peripheral blood lymphocytes and spleen lymphocytes is promoted, the proportion of CD4 +, CD8 + and NK cells is increased, and the effect of enhancing immunity is achieved. Furthermore, the hydrogel CMOT prepared by taking the radix trichosanthis polysaccharide as the raw material has good biocompatibility in vitro and in vivo and has the qualified characteristic of hydrogel, and the CMOT hydrogel is found to have the effect of inhibiting the recurrence of the colorectal cancer when being applied to the resection part of the mouse colorectal cancer operation. Therefore, the radix trichosanthis polysaccharide hydrogel has the potential of becoming a postoperative wound dressing after cancer resection.

This invention relates to the field of biomedical technology, and discloses a 6mA modified single-stranded DNA sequence that specifically binds to the MYH9 protein and its application in the treatment of sepsis; the single-stranded DNA sequence is specifically bound to the MYH9 protein. N 6 A single-stranded DNA sequence modified with 6mA-methyladenine (nucleotide sequence shown in SEQ ID NO:1) exhibits a specific adenine (A) methylation at a specific position, which allows it to be specifically recognized and bound by the MYH9 protein. The binding specificity was verified in vitro / in vivo using EMSA, biotin DNA pulldown WB assays, and MYH9-DNA IP assays. This 6mA-modified single-stranded DNA, by binding to the MYH9 protein, activates the downstream JAK1-STAT6 signaling pathway, promoting macrophage polarization towards the M2 phenotype, inhibiting excessive inflammatory responses, improving survival rates, reducing pathological damage to spleen tissue, and ameliorhythmic symptoms such as weight loss and hypothermia in septic mice, thereby exerting an anti-septic effect. This effectively addresses the clinical pain points of existing non-specific anti-inflammatory therapies and possesses significant potential for drug development.

The invention discloses hydrogel for driving phenotypic conversion from M1 to M2 of macrophages and application of the hydrogel, the hydrogel comprises a matrix and an active component, the matrix is a chitosan quaternary ammonium salt-phenylboronic acid copolymer, and the active component is a fullerol-Apoptozole conjugate APamp formed by covalent coupling of fullerol and a small molecule inhibitor Apoptozole through an acylhydrazone bond; c60; the hydrogel is a fullerol-chitosan hydrogel which can respond to a hyperglycemia and oxidative stress wound microenvironment and can controllably release fullerol and a small molecule inhibitor Apoptozole to block a signal axis of mitochondria HSPA8-ROMO1, the three effects of antibiosis, antioxidation and immunoregulation can be integrated, and a precise treatment scheme is provided for chronic wounds of diabetes mellitus.

The application discloses a novel preparation method and application of hybrid extracellular vesicles. The application combines endothelial cell-derived and neutrophil-derived vesicles with deferoxamine to develop a biological mixed nano-vesicle platform (DFO@HEVs) to solve the problem of diabetic wound healing. The dual-targeting system utilizes CXCR4-mediated endothelial cell homing and beta2 integrin-dependent inflammatory tropism to accurately deliver DFO to the wound site, DFO@HEVs activate HIF-1alpha / VEGF to restore vascular regeneration, inhibit ferroptosis through Nrf2 / GPX4 signaling, and reprogram macrophages into a pro-repair M2 phenotype, effectively breaking the oxidative stress-inflammation-ferroptosis cycle.

This invention discloses a method, system, and apparatus for computer-aided drug screening based on temozolomide and ADAMTS1. This application is the first to discover that ADAMTS1 is significantly enriched in recurrent gliomas following temozolomide exposure; temozolomide strongly induces a stable senescence program, leading to excessive secretion of ADAMTS1. This senescence-induced protease coordinates significant changes in extracellular matrix composition. The remodeled microenvironment acts as a mechanobiochemical signaling agent, recruiting and polarizing host-derived myeloid cells to transform into the immunosuppressive M2 phenotype, thereby conferring chemotherapy resistance to residual glioma cells through paracrine signaling. This application reveals that the "senescence-ADAMTS1-ECM-M2" axis is a key non-cellular autonomous mechanism of temozolomide resistance. Targeting ADAMTS1-mediated matrix reprogramming can eliminate the immunosuppressive niche in gliomas and overcome chemotherapy resistance, showing broad application prospects.

The invention relates to application of a CD300LF small-molecule inhibitor, and belongs to the technical field of medicines. The CD300LF small-molecule inhibitor comprises temopril, and the small-molecule inhibitor temopril taking CD300LF as a target spot is screened from a small-molecule drug library approved by FDA through computer high-throughput virtual drug screening in combination with biological activity screening. The invention reveals that temopril can be used as a CD300LF small-molecule inhibitor, is specifically combined with CD300LF, induces tumor-related macrophages to be converted from an M2 phenotype to an M1 phenotype, enhances the phagocytosis of the macrophages on tumor cells, and shows remarkable inhibition capability on tumor growth in an in-vivo experiment for the first time. In addition, it is found that after temopril and an immune checkpoint inhibitor are combined for use, a remarkable synergistic anti-tumor effect can be generated. The temopril can be used as a potential immunotherapy drug, and is expected to provide an experimental basis and a candidate drug for clinical treatment and prevention of cancers.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The application discloses a preparation method of a 3D printing cerium hydroxyapatite bone repair scaffold material, and comprises the following steps: adding phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate salt powder into manganese-chelated deferoxamine grafted methylacryl gelatin, stirring, adding cerium hydroxyapatite nanowires which are surface-modified by citric acid, and stirring to obtain 3D printing slurry; and the 3D printing slurry is extruded by a 3D printer while being cross-linked by 365nm ultraviolet irradiation to obtain the 3D printing cerium hydroxyapatite bone repair scaffold material; the material has good biocompatibility, can promote vascularization and immune regulation, and can effectively regulate M2 phenotype differentiation of RAW264.7, so that more BMP-2 and PDGF-bb growth factors are secreted, osteogenesis differentiation and angiogenesis are promoted, and bone defect repair is promoted from the perspective of immune regulation.

This invention discloses a network-like porous poly(3,4-hydroxybutyrate) microsphere, its preparation method, and its applications, belonging to the field of biomedical materials technology. The microspheres exhibit a villous network structure with a continuous, irregular "ridge-valley" topology on their surface. The network-like porous poly(3,4-hydroxybutyrate) microspheres provided by this invention maintain good structural integrity even after 6 months of in vivo implantation, significantly increase ATP levels in fibroblasts under glucose-free conditions, and inhibit cell senescence. They also induce macrophages to transform from a pro-inflammatory M1 phenotype to a pro-repair M2 phenotype, avoiding the excessive inflammatory response commonly seen in PLLA-type microspheres, and demonstrate superior collagen regeneration promotion compared to PLLA-type microspheres. Furthermore, they facilitate cell adhesion and proliferation.

The present invention provides a method for producing cells polarized to the M2 phenotype, said method comprising culturing mononuclear phagocyte system cells in a suitable medium comprising lactic acid or a lactic acid derivative, and subjecting said cells to a period of hypoxia followed by a period of reoxygenation. The present invention also provides compositions comprising cells obtained with the method as defined herein and uses thereof.

The application relates to the field of biological medicine, and particularly relates to application of a curcumin compound in preparation of a medicine for treating periodontitis, and comprises the following steps: a mono-carbonyl curcumin analogue with a structure shown in formula (I) is used for preparing the medicine for treating periodontitis, and the compound is obtained by replacing a beta-diketone group of natural curcumin with a mono-carbonyl connecting group. The compound provided by the application has a chemical stability which is significantly better than that of natural curcumin, and solves the problems of easy degradation and low bioavailability; meanwhile, the compound has excellent broad-spectrum anti-periodontal pathogenic bacteria activity and immune regulation capacity, can significantly promote M2 phenotype polarization of macrophages and inhibit generation of key pro-inflammatory cytokines, realizes double effects of antibiosis and immune regulation, and provides a new, efficient and low-toxicity auxiliary treatment medicine for periodontitis.

The application discloses an electroactive fiber membrane for promoting osteogenesis and a preparation method and application thereof. Experimental results show that the electroactive fiber membrane can directly promote macrophages to polarize to an anti-inflammatory M2 phenotype, and can inhibit the inflammatory induction of lipopolysaccharide (LPS) on macrophages, so as to realize the transformation of macrophages from a pro-inflammatory M1 phenotype to an M2 phenotype, and has the effects of inhibiting inflammation and promoting tissue regeneration. Meanwhile, the improvement of the electroactivity of the fiber membrane is beneficial to promoting an electro-physiological microenvironment for osteogenesis, and the fiber membrane can also adsorb cationic substances such as calcium ions in the environment, which is conducive to the occurrence of biological mineralization, so that the fiber membrane can promote osteogenesis.

The invention belongs to the technical field of biomedical materials, and relates to an MMP13-DNA / NVs (at) GA hydrogel sustained-release system and a preparation method and application thereof, and the MMP13-DNA / NVs (at) GA hydrogel sustained-release system is formed by combining aptamer DNA hydrogel with MMP13 response and GA-loaded cell membrane bionic nano-vesicles. Compared with the prior art, the MMP13-DNA / NVs (at) GA hydrogel sustained-release system responds to overexpressed MMP13 in an inflammatory microenvironment, the drug GA for promoting polarization of M1 phenotype macrophages is precisely controlled to drive the M1 phenotype macrophages to be polarized into M2 phenotype, so that TGF-beta is released to promote mesenchymal stem cells to be differentiated into cartilage cells; meanwhile, the accurate delivery efficiency of the vesicles is improved by utilizing cell homology, and a novel strategy with intelligent response and accurate treatment is provided for osteoarthritis treatment.

The application belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of a polyketide compound from a fungus of the genus Arenarius. The polyketide compound can dose-dependently reduce the NO generation level in cells, significantly inhibit M1 phenotype polarization and promote the conversion of the M1 phenotype to the M2 phenotype, significantly down-regulate the expression of key inflammatory-related proteins (including IL-1beta, IL-6, TNF-alpha and COX-2) in cells, and inhibit the generation of NLRP3 inflammasome and caspase-1, revealing the potential anti-AD activity and indicating that the polyketide compound has a good application prospect in the preparation of anti-neuroinflammatory drugs. In addition, the polyketide compound can be prepared from a marine microorganism Arenarius fungus, and the preparation method is simple and the source is rich.

Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The invention provides an active oxygen responsive hydrogen sulfide donor, an active oxygen responsive hydrogen sulfide controlled release type cationized chitosan sponge as well as a preparation method and application thereof, and belongs to the field of medical materials. The active oxygen responsive hydrogen sulfide controlled release type cationized chitosan sponge prepared from quaternized chitosan and an active oxygen responsive hydrogen sulfide donor can controllably release hydrogen sulfide as required under the stimulation of active oxygen, can reduce the level of active oxygen in cells, can improve the level of hydrogen sulfide, and can inhibit the activation of NF-kappa B so as to improve the activity of hydrogen sulfide. The traditional Chinese medicine composition can be used for regulating macrophage phenotype polarization to M2, reducing cell inflammatory factor expression, eliminating excessive inflammation, enhancing migration and angiogenesis capability of human umbilical vein endothelial cells, promoting reepithelization, collagen deposition and angiogenesis, relieving inflammatory response and accelerating healing of diabetic wounds at the same time. The prepared active oxygen response hydrogen sulfide controlled release type cationized chitosan sponge provides a promising solution for diabetic wound repair.

The invention belongs to the field of biomedicine, and particularly relates to application of Ptpn6 knockout macrophages in breast cancer radiotherapy sensitization. Through experimental verification for the first time, Ptpn6 is determined as a key new target for regulating and controlling radiation response and functional phenotype of macrophages. The Ptpn6 gene of the macrophage is knocked out through a gene editing technology, the radiation resistance of the macrophage can be enhanced, the macrophage can continuously survive in a microenvironment after radiotherapy, the macrophage can be reprogrammed into an anti-tumor M1 sample phenotype from a tumor promoting M2 phenotype, and then the anti-tumor immunocompetence of the macrophage is enhanced. In-vitro and in-vivo experiments prove that compared with wild type macrophages, the Ptpn6 knockout macrophages can be used as a cell sensitizer to be combined with radiotherapy, so that the proliferation of tumor cells can be more effectively inhibited, the apoptosis of the tumor cells can be promoted, and the growth of in-vivo tumors can be obviously inhibited. A brand new cell treatment strategy is provided for overcoming breast cancer radiotherapy resistance.

This invention discloses a reactive oxygen species (ROS) responsive glycyrrhizic acid anti-inflammatory hydrogel and its application in the preparation of drugs for treating compressive neuropathic pain. Belonging to the field of biomedical materials technology, the hydrogel uses glycyrrhizic acid and 1,4-phenylboronic acid as raw materials. It is heated in an alkaline environment until a homogeneous mixed solution is formed, and then naturally cooled to room temperature to obtain the ROS responsive glycyrrhizic acid anti-inflammatory hydrogel. This hydrogel possesses good injectability, self-healing properties, biocompatibility, and biodegradability. It can specifically cleave borate ester bonds in the highly reactive oxygen species pathological microenvironment of diabetic patients with lumbar disc herniation, releasing glycyrrhizic acid on demand. By targeting and regulating the PI3K-AKT signaling pathway, it promotes the polarization of macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype, significantly inhibiting the inflammatory response of the dorsal root ganglion and the dorsal horn of the spinal cord, effectively relieving compressive neuropathic pain in the dorsal root ganglion caused by diabetic patients with lumbar disc herniation, and has good prospects for clinical translation.

The invention discloses an ion-immune-electric coupling 3D bionic conductive catheter and a preparation method and application thereof, and belongs to the technical field of biomedical materials. According to the catheter, a gelatin / poly-L-lactic acid / polypyrrole nanofiber scaffold serves as a substrate, tannic acid and magnesium ions are loaded in sequence, and a three-dimensional bionic structure with electrical conductivity, ion slow release and immunoregulation functions is formed. The conductivity of the catheter is matched with that of the natural spinal cord, Mg can be continuously released to reduce excitatory toxicity of neurons, and macrophages are synergistically regulated and controlled to be polarized to M2 phenotype through tannic acid, so that oxidative stress and inflammation are relieved. In-vitro experiments show that the catheter can promote neural stem cells to differentiate into neurons and inhibit activation of astrocytes. In a rat full-cross-section spinal cord injury model, when the catheter is implanted, axon regeneration, myelin sheath formation and synaptic occurrence can be remarkably promoted, movement and urinary function recovery are effectively improved, and an innovative treatment strategy is provided for spinal cord injury repair.